CompletedPhase 1

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

United States430 participantsStarted 2023-12-04

Plain-language summary

To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male or non-pregnant female aged ≥ 18 years
✓. Subjects must have provided IRB approved written informed consent.
✓. Subjects must have clinical diagnosis of tinea versicolor.
✓. Subjects must be willing to refrain from using all other tinea versicolor medications or antifungals during the study, other than the investigational product.
✓. Female Subjects of childbearing potential (excluding women who are premenarchal, surgically sterilized (by hysterectomy) or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug.

Exclusion criteria

✕. Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
✕. Subjects with a history of hypersensitivity or allergy to ketoconazole, other imidazole antifungals, and/or any of the study medication ingredients.
✕. Subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of tinea versicolor (e.g., vitiligo, pityriasis alba, post inflammatory hypopigmentation and hyperpigmentation, seborrheic dermatitis, pityriasis rosea, guttate psoriasis, tinea corporis, nummular eczema, secondary syphilis, confluent reticulated papillomatosis of Gougerot and Carteaud, and mycosis fungoides).
✕. Treatment for tinea versicolor within the past 6 months that had been unresponsive to prescription topical or oral antifungals.

What they're measuring

To demonstrate the therapeutic equivalence and safety of the Investigational Product

Timeframe: Day 28 Visit

Trial details

NCT IDNCT06305637

SponsorSun Pharmaceutical Industries, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-02-10

View on ClinicalTrials.gov More Tinea Versicolor trials